FDA approves Vivus’s fast-acting Viagra rival

<p>NEW YORK (Reuters) – Men with <span>erectile dysfunction</span> might not have to devise for sex as distant in allege anymore after <span>Vivus Inc</span> won U.S. capitulation for avanafil, a faster behaving opposition to Viagra.</p>
<p> Avanafil, that will be sole underneath a code name Stendra, is a initial new drug in a difficulty in a decade.</p>
<p> The drug — that will contest with <span>Pfizer Inc</span>‘s Viagra, <span>Eli Lilly</span>‘s Cialis and Levitra, sole by GlaxoSmithKline and Bayer — gives <span>Vivus</span>, that has struggled to move a <span>weight detriment drug</span> to market, a potentially remunerative blurb product.</p>
<p> The Vivus drug will have some appealing selling claims as it goes adult opposite determined rivals sole by companies with critical selling muscle.</p>
<p> “This ...